AACR Annual Meeting | Conference

Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer

April 18th 2016

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

PARP/AKT Inhibitor Combination Active in Multiple Tumor Types

April 18th 2016

The combination of the PARP inhibitor olaparib and the investigational AKT inhibitor AZD5363 resulted in durable responses in patients with solid tumors, with and without BRCA mutations.

Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation

April 18th 2016

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

Palbociclib Showed Antiproliferative Activity in Early-stage Breast Cancer

April 18th 2016

Palbociclib may have antiproliferative effects when used as a neoadjuvant therapy for women with early stage breast cancer.

70-Gene Signature Identifies Breast Cancer Subgroup Unlikely to Benefit From Adjuvant Chemo

April 18th 2016

A 70-gene signature (MammaPrint) demonstrated a high level of accuracy at identifying a large subset of women with clinically high-risk early stage breast cancer for whom adjuvant chemotherapy was unlikely to produce benefit.

Dr. Postow on OS Results of CheckMate-069 Study

April 18th 2016

Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the overall survival (OS) results of the CheckMate-069 study, which investigated the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

Nivolumab/Ipilimumab Combination Shows Survival Benefit in Advanced Melanoma

April 18th 2016

The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) showed a 42% improvement in overall survival compared with ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment of the phase II CheckMate-069 trial.

Yong-Chen William Lu on Adoptive T-Cell Therapy in Solid Tumors

April 18th 2016

Yong-Chen William Lu, PhD, a fellow in the Surgery Branch of the National Cancer Institute, discusses a CD4 T-cell immunotherapy targeting MAGE-A3 that is showing early clinical responses in patients with metastatic cancer.

Dr. Lai on Risk Factors Associated With Glioma

April 17th 2016

Rose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses results of the Glioma International Case Control study.

Entrectinib Achieves High Response Rate Across Solid Tumors

April 17th 2016

Treatment with the novel multikinase inhibitor entrectinib achieved objective responses in 79% of patients with solid tumors associated with NTRK, ROS-1, or ALK rearrangements.

MAGE-A3—Targeted Adoptive T-Cell Therapy Shows Promise in Solid Tumors

April 17th 2016

A form of immunotherapy that harnesses the power of CD4 T-cells was shown to be safe and effective in patients with various types of metastatic cancers.

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

April 17th 2016

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

Nivolumab Shows Impressive Long-Term OS in Melanoma

April 17th 2016

Single-agent nivolumab demonstrated a robust 5-year overall survival rate of 34% for heavily pretreated patients with metastatic melanoma who had not received prior ipilimumab.

Dr. Camidge on MET as a Target in Lung Cancer

April 23rd 2015

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET and if it is still a relevant target in lung cancer.

Dr. Shaw on Overcoming Resistance in Lung Cancer

April 23rd 2015

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Dr. Bast on Earlier Detection of Ovarian Cancer

April 22nd 2015

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

Olaparib Proves Versatile When Paired With AKT Inhibitor

April 22nd 2015

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

Dr. Herbst on Nivolumab for NSCLC

April 22nd 2015

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.

Olaparib Plus BKM120 Combo Gains Traction in Breast and Ovarian Cancers

April 21st 2015

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Dr. Mittendorf on Nelipepimut-S in Breast Cancer

April 21st 2015

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).